Patrick Daly

DocwireNews

Following results from the <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2019422">EAST-AFNET4</a> trial, which demonstrated clinical benefits of early rhythm control in patients with atrial fibrillation, researchers, led by Shinwan Kany, applied the trial&rsquo;s inclusion/exclusion criteria to the UK Biobank to assess the generalizability of the trial&rsquo;s findings. According to their study, published in Heart, approximately 80% of patients with atrial fibrillation in the UK population were eligible for early therapy.The authors also concluded that early rhythm control therapy via antiarrhythmic drug therapy or atrial fibrillation ablation was safe during the routine care of patients with atrial fibrillation.The researchers identified 35,562 patients with atrial fibrillation out of 502,493 (7.1%) participants in the UK Biobank, of which 8,340 had atrial fibrillation at enrollment and 27,186 developed incident atrial fibrillation during follow-up. Hospital Episode Statistics data were compared to UK Biobank data to evaluate early rhythm control impact, and safety and efficacy was compared between the cohort and a propensity-matched group.<h3>Viability of Early Rhythm Control in Atrial Fibrillation</h3>The authors found that 22,003 of 27,186 (80.9%) patients with incident atrial fibrillation were eligible for early rhythm control based on the EAST-AFNET4 enrollment criteria. Additionally, eligible patients were on average older (70 vs. 63 years) and more likely to be female (42% vs. 21%) compared to ineligible individuals.Among 9,004 patients with full primary care records available, 874 (9.02%) had received early rhythm control therapy. These patients showed no additional safety signals compared to controls. Furthermore, patients who received early rhythm control had a lower incidence of the primary composite outcome of EAST-AFNET4 (cardiovascular death, stroke/transient ischemic attack, and hospitalization for heart failure or acute coronary syndrome) compared to controls in the full cohort (hazard ratio [HR] 0.82; 95% confidence interval [CI], 0.71-0.94; P=.005). Finally, early therapy did not significantly decrease the primary outcome compared to usual care in propensity matched comparisons (HR 0.87; 95% CI, 0.72-1.04; P=.124), which the authors suggested was &ldquo;likely due to smaller absolute effect estimator and low power.&rdquo;Ultimately, Kany and colleagues stated that &ldquo;early rhythm control should become a routine part of the clinical management of most patients with recently diagnosed AF.&rdquo;Find more recent studies on the <a href="https://www.docwirenews.com/atrial-fibrillation/">Atrial Fibrillation Knowledge Hub</a>

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Generalizability of Trial Findings Supporting Early Rhythm Control in Atrial Fibrillation

Atrial Fibrillation

Following results from the EAST-AFNET4 trial, which demonstrated clinical benefits of early rhythm control in patients with atrial fibrillation, researchers, led by Shinwan ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe